Antithrombotic properties of RWJ-50353, a potent and novel thrombin inhibitor

Thrombosis Research

Volumn 98, Issue 1, 2000, Pages 83-93

  Giardino, Edward C ^a   Costanzo, Michael J ^a   Kauffman, Jack A ^a   Li, Quan Sheng ^a   Maryanoff, Bruce E ^a   Andrade Gordon, Patricia ^a  

^a R W JOHNSON PHARMACEUTICAL RES I   (United States)

Author keywords

Antithrombotic; Arteriovenous shunt; Deep vein thrombosis; Platelet aggregation; Thrombin inhibitor

Indexed keywords

ANTICOAGULANT AGENT; ARGATROBAN; EFEGATRAN; HEPARIN; RWJ 50353; THROMBIN INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERIOVENOUS SHUNT; ARTICLE; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; HUMAN; HUMAN CELL; MALE; NONHUMAN; PRIORITY JOURNAL; RABBIT; THROMBOCYTE AGGREGATION; THROMBOGENESIS;

ANIMALS; BLOOD PLATELETS; DOGS; FIBRINOLYTIC AGENTS; GUANIDINES; HEMOSTATICS; HUMANS; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; RABBITS; THIAZOLES; THROMBIN;

EID: 0034003115     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(99)00219-4     Document Type: Article

References (29)

1. Becker R.C. Thrombin antagonists and antiplatelet agents. Am J Cardiol. 69:1992;39A-51A.
2. Ip J.H., Fuster V., Badimon L. Thrombosis and antithrombotic therapy in cardiovascular disease. Cardiovascular Rev Rep. 12:1991;16-30.
3. Chesebro J.H., Webster M.W.I., Zoldhelyi P., Roche P.C., Badimon L., Badimon J.J. Antithrombotic therapy and progression of coronary artery disease. Circulation. 86(6 (Suppl. III)):1992;100-111.
4. Bergqvist D. New approaches to prevention of deep vein thrombosis. Thromb Haemost. 78:1997;684-688.
5. Davie E.W., Fujikawa K., Kisiel W. The coagulation cascade. Initiation, maintenance and regulation Biochemistry. 30:1991;10363-10370.
6. Badimon L., Meyer B.J., Badimon J.J. Thrombin in arterial thrombosis. Haemostasis. 24:1994;69-80.
7. Stubbs M.T., Bode W. Coagulation factors and their inhibitors. Curr Opin Struc Biol. 4:1994;823-832.
8. Tapparelli C., Metternich R., Ehrhardt C., Cook N.S. Synthetic low-molecular weight thrombin inhibitors. Molecular design and pharmacological profile Trends Pharm. 14:1993;366-376.
9. Harker L.A., Hanson S.R., Kelly A.B. Antithrombotic strategies targeting thrombin activities, thrombin receptors and thrombin generation. Thromb Haemost. 78:1997;736-741.
10. Olsen S.T., Bjork I. Regulation of thrombin activity by antithrombin and heparin. Semin Thromb Hemost. 20:1994;373-408.
11. Verstraete M. Direct thrombin inhibitors. Appraisal of the antithrombotic/hemorrhagic balance Thromb Haemost. 78:1997;357-363.
12. Chi L., Rogers K.L., Uprichard A.C.G., Gallagher K.P. The therapeutic potential of novel anticoagulants. Exp Opin Invest Drugs. 6:1997;1591-1622.
13. Weitz J.I., Hirsh J. Antithrombins. Their potential as antithrombotic agents Annu Rev Med. 43:1992;9-16.
14. Turpie A.G. Successors to heparin. New antithrombotic agents Am Heart J. 134:1997;S71-S77.
15. Wallis R.B. Inhibition of thrombin, a key step in thrombosis. Drugs of Today. 25:1989;597-605.
16. Deutsch E., Rao A.K., Colman R.W. Selective thrombin inhibitors. The next generation of anticoagulants J Am Coll Cardiol. 22:1993;1089-1092.
17. Hermann J.R., Kutryk J.B., Serruys P.W. Clinical trials of direct thrombin inhibitors during invasive procedures. Thromb Haemost. 78:1997;367-376.
18. Schumacher W.A., Heran C.L., Steinbacher T.E. Low-molecular-weight heparin (fragmin) and thrombin active-site inhibitor (argatroban) compared in experimental arterial and venous thrombosis and bleeding time. J Cardiovasc Pharmacol. 28:1996;19-25.
19. Sudo Y., Lucchesi B.R. Antithrombotic effect of GYKI-14766 in a canine model of arterial and venous rethrombosis. A comparison with heparin J Cardiovasc Pharmacol. 27:1996;545-555.
20. Jang I.K., Gold H.K., Ziskind A.A., Leinbach R.C., Fallon J.T., Collen D. Prevention of platelet-rich arterial thrombosis by selective thrombin inhibition. Circulation. 81:1990;219-225.
21. Maffrand J.P. Direct thrombin inhibitors. Nouv Rev Fr Haematol. 34:1992;405-419.
22. Weitz J.I., Hudoba M., Massel D., Maraganore J., Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest. 86:1990;385-391.
23. Costanzo M.J., Maryanoff B.E., Hecker L.R., Schott M.R., Yabut S.C., Zhang H.-C., Andrade-Gordon P., Kauffman J.A., Lewis J.M., Krishnan R., Tulinsky A. Potent thrombin inhibitors that probe the S1′ subsite. Tripeptide transition state analogues based on a heterocycle-activated carbonyl group J Med Chem. 39:1996;3039-3043.
24. Mehdi S. Synthetic and naturally occurring protease inhibitors containing an electrophilic carbonyl group. Bioorg Chem. 21:1993;249-259.
25. Williams J.W., Morrison J.F. The kinetics of reversible tight-binding inhibition. Methods Enzymol. 63:1979;437-467.
26. Bagdy D., Szabo G., Barabas E., Bajusz S. Inhibition by D-MePhe-Pro-Arg-H (GYKI-14766) of thrombus growth in experimental models of thrombosis. Thromb Haemost. 68:1992;125-129.
27. 1 and argatroban J Pharmacol Exp Ther. 277:1996;502-510.
28. Berry C.N., Girard D., Girardot C., Lochot S., Lunven C., Visconte C. Antithrombotic activity of argatroban in experimental thrombosis in the rabbit. Semin Thromb Hemost. 22:1996;233-241.
29. Hoffmann P., Bernat A., Savi P., Herbert J.M. Antiplatelet and antithrombotic efficacy of SR 121787, a nonpeptide orally active GPIIb/IIIa antogonist, in rabbits. Comparison with clopidogrel and aspirin J Cardiovasc Pharmacol. 30:1997;360-366.